Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Tempus AI
NRG Oncology
Elevation Oncology
Inhibrx Biosciences, Inc
Pfizer
Fusion Pharmaceuticals Inc.
Rutgers, The State University of New Jersey
pharmaand GmbH
Fate Therapeutics
Fred Hutchinson Cancer Center
West Virginia University
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Tetra Bio-Pharma
InSightec
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Wisconsin, Madison
Yale University
University of Kentucky
CureOne
National Institutes of Health Clinical Center (CC)
University of Pittsburgh
University of Florida
Virginia Commonwealth University
Masonic Cancer Center, University of Minnesota
New York State Psychiatric Institute
Virginia Commonwealth University
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Pharmacyclics LLC.
Pfizer
Calando Pharmaceuticals
New Mexico Cancer Research Alliance
National Cancer Institute (NCI)
Auron Healthcare GmbH
Emory University
The University of Texas Health Science Center at San Antonio
University of Wisconsin, Madison